Related by context. All words. (Click for frequent words.) 68 myotonic muscular dystrophy 62 AA Amyloidosis 61 Idiopathic Pulmonary Fibrosis 61 recurrent glioblastoma multiforme 61 relapsing multiple sclerosis 60 Glioblastoma Multiforme 60 Acute Myeloid Leukaemia AML 60 Severe Sepsis 60 pancreatic insufficiency 60 Myelodysplastic Syndrome MDS 60 Major Depressive Disorder MDD 60 Lupus Nephritis 59 TTR amyloidosis 59 relapsed leukemia 59 Rheumatoid Arthritis RA 59 Chronic lymphocytic leukemia 59 SNT-MC#/idebenone 59 ISTODAX ® 59 Investigational Treatment 59 Pulmonary Arterial Hypertension 58 Chronic Myeloid Leukemia 58 chronic granulomatous disease 58 overactive bladder syndrome 58 atypical hemolytic uremic syndrome 58 Phase Ib clinical 58 immune thrombocytopenic purpura ITP 58 LHON 58 Acute Leukemia 58 metastatic malignant 58 refractory chronic lymphocytic 58 Frozen Shoulder Syndrome 58 Acute Promyelocytic Leukemia 58 mitoxantrone plus 58 Fabry Disease 58 smoldering multiple myeloma 58 Acute Myelogenous Leukemia AML 58 leukemia AML 57 non metastatic osteosarcoma 57 MELAS 57 Leber Hereditary Optic Neuropathy 57 CYT# potent vascular disrupting 57 haematological cancers 57 Chronic Lymphocytic Leukemia 57 Myelodysplastic Syndromes 57 Chronic Myelogenous Leukemia 57 Omacetaxine 57 severe malignant osteopetrosis 57 chorea associated 57 Nephrotic Syndrome 57 metastatic gastric 57 Critical Limb Ischemia 57 Renal Cell Carcinoma RCC 57 Asthma COPD 57 Natalizumab 57 Phase #b/#a clinical 57 Relapsed Refractory 57 refractory acute myeloid 57 relapsing remitting MS RRMS 57 Rilonacept 57 Lennox Gastaut syndrome 57 Cimzia TM 57 leukemia ALL 57 untreated multiple myeloma 57 Aryplase 57 alpha1 antitrypsin deficiency 57 Mantle Cell Lymphoma 57 Paroxysmal Nocturnal Hemoglobinuria PNH 57 Diabetic Neuropathy 57 acetonide FA 57 Severe Primary IGFD 57 Friedreich Ataxia 57 Acute Myelogenous Leukemia 56 Renal Cell Carcinoma 56 chronic idiopathic thrombocytopenic purpura 56 chronic thromboembolic pulmonary 56 Arzerra ofatumumab 56 Phase Ib IIa 56 Juvenile Idiopathic Arthritis 56 pediatric Crohn disease 56 Pegylated Interferon 56 Alemtuzumab 56 Pharmacokinetics PK 56 biliary tract cancer 56 randomized Phase IIb 56 myeloid metaplasia 56 Myelofibrosis 56 bladder carcinoma 56 LHRH receptor positive 56 neurogenic bladder 56 Neuroendocrine Tumors 56 omacetaxine mepesuccinate 56 Cloretazine 56 Heterozygous Familial Hypercholesterolemia 56 Leukemias 56 Acute Lymphoblastic Leukaemia 56 gastrointestinal stromal tumor GIST 56 Vidaza azacitidine 56 Hepatitis C Virus 56 dirucotide MBP# 56 Chronic Sinusitis 56 severe oral mucositis 56 eosinophilic asthma 56 Veno Occlusive Disease 56 commercialize deforolimus 56 metastatic malignant melanoma 56 Acute Myeloid Leukemia AML 56 Aviptadil 56 T Cell Lymphoma 56 mildly symptomatic 56 CIMZIA TM certolizumab pegol 56 ATTR CM 56 patientswith 56 transthyretin amyloidosis 56 imatinib resistance 56 TB Vaccine 56 refractory Hodgkin 56 dilated cardiomyopathy DCM 56 Familial Hypercholesterolemia 56 Progressive Multifocal Leukoencephalopathy 56 OHR/AVR# 56 dual endothelin receptor antagonist 56 Rheumatoid 56 pulmonary hypertension PH 56 MPS VI 56 Diabetic Nephropathy 56 Xanafide 56 Philadelphia Chromosome Positive 56 PD LID 56 Acute Renal Failure 56 SPRYCEL ® 55 essential thrombocythemia ET 55 Zarnestra 55 Acute myeloid leukemia 55 refractory myeloma 55 tumors GIST 55 Pafuramidine 55 acute myeloid 55 chronic myeloid 55 post herpetic neuralgia PHN 55 HP Acthar Gel repository 55 refractory metastatic 55 Antiretroviral ARV 55 Acute Myeloid Leukemia 55 Maribavir 55 recurrent metastatic 55 psoriatic arthritis PsA 55 lymphocytic leukemia 55 CTEPH 55 HIV coinfected 55 AVONEX ® 55 Bayer HealthCare Onyx Pharmaceuticals 55 uremic pruritus 55 BrachySil TM 55 cognitive impairment associated 55 von Willebrand Disease 55 Ranibizumab 55 Etanercept 55 serum biomarker 55 Decitabine 55 Pulmonary Arterial Hypertension PAH 55 Systemic Lupus Erythematosus SLE 55 Soft Tissue Sarcoma 55 SUTENT ® 55 Glufosfamide 55 Nilotinib 55 Advanced Melanoma 55 LymphoStat B TM 55 Gemzar ® 55 polyarticular 55 alemtuzumab Campath 55 smoldering myeloma 55 SJIA 55 retinal vein occlusion induced 55 Diabetic Foot Ulcer 55 opioid induced constipation OIC 55 rheumatoid arthritis Crohn disease 55 PKC# 55 Preclinical Models 55 Malignant Melanoma 55 Initiates Enrollment 55 Unresectable 55 metastatic colorectal carcinoma 55 Leber Congenital Amaurosis LCA 55 Phase 1b clinical 55 Previously Untreated 55 Alequel 55 adjuvant cisplatin 55 tuberous sclerosis TS 55 Annamycin 55 ErbB2 positive 55 Cutaneous T 55 Peripheral Artery Disease 55 keloid scarring 55 hepatorenal syndrome 55 Bronchiectasis 55 Shows Efficacy 55 recurrent malignant glioma 55 JAK2 Inhibitor 55 haematologic malignancies 55 refractory prostate cancer 55 hypophosphatasia 55 Quinamed 55 Pelvic Organ Prolapse 55 Cardiotoxicity 55 multiple myeloma MM 55 huN# DM1 55 Tolvaptan 55 Improves Outcomes 55 Neovascular Age Related Macular 55 recurrent NSCLC 55 Chronic Heart Failure 55 idiopathic pulmonary fibrosis IPF 55 Renal Cancer 55 acute myelogenous leukemia AML 55 FOLOTYN ® 55 Aflibercept 55 Ischemic 55 constipation OIC 55 IIa trials 55 anaplastic astrocytoma 55 Rheumatoid Arthritis 54 Chronic Lymphocytic Leukemia CLL 54 Dupuytren Contracture 54 metastatic bladder 54 Diabetic Retinopathy 54 relapsed MM 54 CVBT #H 54 myasthenia gravis MG 54 Diabetic Macular Edema 54 Initiates Clinical Trial 54 Overactive Bladder 54 systemic amyloidosis 54 idiopathic thrombocytopenic purpura ITP 54 Sjogren Syndrome 54 HeFH 54 CALGB # [002] 54 Diagnostic Criteria 54 essential thrombocythemia 54 Syncria R 54 Newly Diagnosed Multiple Myeloma 54 Disease Progression 54 Eculizumab 54 complement inhibitor eculizumab 54 refractory colorectal cancer 54 Morquio 54 Ribavirin causes 54 Severe VOD 54 octreotide implant 54 hypereosinophilic syndrome 54 CIPN 54 Systemic Sclerosis 54 nonalcoholic steatohepatitis NASH 54 Intravenous immunoglobulin 54 completely resected 54 Phase III Trial 54 receptor tyrosine kinase inhibitor 54 ZACTIMA 54 BrachySil ™ 54 metastatic bone 54 Slow Progression 54 Denufosol 54 AA amyloidosis 54 Lipodystrophy 54 Hurler syndrome 54 hormone refractory metastatic prostate 54 drug NP2 Enkephalin 54 Cystic 54 abacavir Ziagen 54 Treatment Shows Promise 54 Enzastaurin 54 Hodgkin lymphoma HL 54 CEQ# 54 systemic fungal infections 54 Ceflatonin R 54 Carcinoid 54 Associated Diarrhea 54 cisplatin chemotherapy 54 Castration Resistant Prostate Cancer 54 Phase 2b Clinical Trial 54 inoperable pancreatic cancer 54 demonstrated antitumor activity 54 refractory metastatic colorectal cancer 54 DCVax ® Brain 54 farletuzumab 54 TMS Therapy 54 Hedgehog Pathway Inhibitor 54 Myelodysplastic Syndrome 54 Relapsing Remitting Multiple Sclerosis 54 Age Related Macular 54 Juvenile Rheumatoid Arthritis 54 Hepatocellular Carcinoma HCC 54 Oral Fingolimod 54 dacarbazine DTIC 54 diabetic gastroparesis 54 Romidepsin 54 Acute Leukaemia 54 Preclinical Efficacy 54 Diabetic Macular Edema DME 54 refractory anaplastic astrocytoma 54 Myelodysplastic syndrome 54 non splenectomized 54 lupus erythematosus 54 Cinquil 54 basiliximab 54 Integrase Inhibitor 54 Daclizumab 54 subependymal giant cell 54 systemic juvenile idiopathic 54 Chronic Fatigue Syndrome CFS 54 placebo controlled clinical 54 Retinitis Pigmentosa RP 54 Gastrointestinal GI 54 Neuropathic Pain 54 trial evaluating PRX# 54 Glioblastoma Multiforme GBM 54 de novo AML 54 refractory gout 54 p# biomarker 54 autosomal recessive genetic 54 Combo Therapy 54 Hepatocellular Carcinoma 54 oxypurinol 54 follicular Non Hodgkin 54 diabetes mellitus DM 54 B Cell Lymphoma 53 systemic mastocytosis 53 Golimumab 53 rheumatoid arthritis psoriatic arthritis 53 Neoadjuvant 53 phase IIa clinical 53 progressive neurodegenerative 53 Edge STudy 53 stage IIIB 53 pediatric malignancies 53 Dyskinesia 53 CTAP# Capsules 53 Ceflatonin 53 multicenter randomized controlled 53 myeloproliferative neoplasms 53 nonmetastatic 53 recurrent glioblastoma 53 Gleevec resistant 53 Chemotherapy induced 53 colorectal liver metastases 53 polycythemia vera essential thrombocythemia 53 idiopathic thrombocytopenic purpura 53 Spinal Muscular Atrophy SMA 53 BCR ABL inhibitor 53 familial amyloidotic polyneuropathy FAP 53 NASH Huntington 53 Pemetrexed 53 thrombotic thrombocytopenic purpura 53 Phase IIa Clinical Trial 53 immune thrombocytopenic purpura 53 occlusion CRVO 53 Bucindolol 53 Enzyme Replacement Therapy 53 Therapeutic Vaccine 53 somatostatin analog 53 Intervention Effectiveness 53 PAOD 53 Atypical Hemolytic Uremic Syndrome 53 Naive Patients 53 Schizoaffective Disorder 53 progressive neurodegenerative disorder 53 paroxysmal nocturnal hemoglobinuria PNH 53 antibody MAb 53 Bezielle 53 relapsed acute lymphoblastic 53 Parkinson Disease PD 53 Amgen Neulasta R 53 Triapine 53 Acute Heart Failure 53 rheumatoid arthritis osteoarthritis ankylosing 53 relapsed multiple myeloma 53 autosomal dominant polycystic kidney 53 leukemia CML 53 Nonalcoholic Fatty Liver Disease 53 DEB# 53 cell lymphoma CTCL 53 Associated Adipose Redistribution 53 Dilated Cardiomyopathy 53 acute GvHD 53 chronic myocardial ischemia 53 BRIM2 53 Atopic Dermatitis 53 Waldenstrom macroglobulinemia 53 minimally symptomatic 53 Chronic Myeloid Leukemia CML 53 erythematosus 53 refractory CLL 53 1 diabetes T1D 53 Chronic Obstructive Pulmonary 53 Non Alcoholic Fatty 53 PEG IFN 53 Amgen Neulasta ® 53 INSPIRE Trial Phase III 53 Huntingtons disease 53 Kit CD# positive 53 erlotinib Tarceva ® 53 sunitinib malate 53 demethylating agent 53 Nesiritide 53 mertansine 53 phase IIb clinical 53 Acute Decompensated Heart Failure 53 Doxil ® 53 Prospective Randomized 53 Iron Deficiency Anemia 53 myeloproliferative 53 Pulmonary Hypertension 53 virus HCV 53 cystic fibrosis chronic pancreatitis 53 Advanced Renal Cell 53 Infected Patients 53 chronic rheumatic 53 hyperphenylalaninemia HPA due 53 Secondary Hyperparathyroidism 53 Diabetic Peripheral Neuropathy 53 Efficacy Results 53 Gleevec imatinib mesylate 53 gastrointestinal stromal tumors GIST 53 stage IIIb IV 53 Cell Lymphoma 53 ara C 53 malignant lymphomas 53 Vitrasert ® 53 Major Depressive Disorder 53 Chronic Bronchitis 53 unresectable tumors 53 EXJADE 53 Diastolic Heart Failure 53 Respiratory Virus 53 Silodosin 53 hematological malignancy 53 Maroteaux Lamy syndrome 53 Therapy Evaluation 53 Adrenomyeloneuropathy AMN 53 refractory angina 53 TroVax ® 53 Brentuximab Vedotin SGN 53 interstitial cystitis IC 53 stage IIIb 52 ADPKD 52 Tramiprosate ALZHEMED TM 52 melphalan prednisone 52 assessing T DM1 52 Community Acquired Pneumonia 52 Treating Chronic 52 leukodystrophies 52 chronic renal disease 52 Cloretazine R 52 immuno inflammatory diseases 52 INxin 52 evaluating tivozanib 52 CLL SLL 52 Parkinsonian Syndromes 52 Irritable Bowel 52 Hematologic 52 Initiates Phase 2b 52 Ozarelix 52 familial hypercholesterolemia FH 52 Monoclonal antibody 52 AML acute myeloid 52 cytomegalovirus infection 52 Oral Fluid 52 YONDELIS R 52 hereditary degenerative 52 IV NSCLC 52 Nitazoxanide 52 metastatic neuroendocrine tumors 52 mGluR2 NAM 52 discoid lupus 52 muscular dystrophy cystic fibrosis 52 Combination REOLYSIN R 52 non resectable 52 HoFH 52 Critical Limb Ischemia CLI 52 Stage IIB 52 ankylosing spondylitis AS 52 rilonacept 52 multiple sclerosis lupus 52 myeloproliferative disorder 52 IMA# 52 Carcinoid Syndrome 52 Glioma 52 chronic renal insufficiency 52 unresectable stage 52 heterozygous FH 52 Allergic Rhinitis 52 Malignant Glioma 52 Interstitial cystitis 52 non hodgkin lymphoma 52 cancer cachexia 52 bevacizumab Avastin 52 Navelbine ® 52 systemic anaplastic large 52 papillary renal cell carcinoma 52 Follicular Lymphoma 52 Duchenne Muscular Dystrophy DMD 52 NOMID 52 relapsed ovarian cancer 52 Squamous Cell Carcinoma 52 Aplidin 52 Diabetic Ulcers 52 Heart Failure Patients 52 PI3K/Akt pathway inhibitor 52 Stakeholder Opinions 52 Lymphocytic 52 gastrointestinal GI disorders 52 levodopa induced 52 diagnosed Ph + 52 advanced hepatocellular carcinoma 52 Parkinsons disease 52 overactive bladder OAB 52 Clinical Trial Results 52 Metastatic Melanoma 52 leukemia CLL 52 Acute Ischemic Stroke 52 Unstable Angina 52 IIa clinical trials 52 Gastric Cancer 52 metastatic pancreatic 52 Refractory Hodgkin Lymphoma 52 alvespimycin 52 activating mutation 52 Myeloid 52 acute leukemias 52 invasive candidiasis 52 Idiopathic Pulmonary Fibrosis IPF 52 Investigational Drug 52 evaluating mipomersen 52 Randomised 52 kidney urologic 52 aMCI precursor 52 Synovial Sarcoma 52 JAK#/JAK# inhibitor CYT# 52 Acute Exacerbations 52 BRAF V#E mutation 52 Acute Lymphoblastic Leukemia 52 disease GERD 52 alemtuzumab treated 52 Metabolic Disorder 52 Albuferon TM 52 neovascular diseases 52 OMNARIS HFA 52 GRN# 52 Retreatment 52 multicenter Phase II 52 refractory AML 52 IBS C 52 homozygous FH 52 rhabdoid 52 primary immunodeficiency PI 52 arthritis PsA 52 MGd 52 inherited neurodegenerative 52 satraplatin Phase 52 retinitis pigmentosa RP 52 neuropathic pain spasticity 52 malignant pleural mesothelioma MPM 52 neurogenic orthostatic hypotension 52 T2DM 52 generalized anxiety disorder GAD 52 rasagiline tablets 52 doublet chemotherapy 52 fallopian tube carcinoma 52 Glatiramer Acetate 52 medullary thyroid carcinoma 52 Metastatic Colorectal Cancer 52 initiated Phase Ib 52 Alzheimer disease cognitive impairment 52 Pemphigus 52 GvHD 52 Subgroup Analysis 52 epilepsy multiple sclerosis 52 HER2 Positive Breast Cancer 52 neurological manifestations 52 Acute Myeloid Leukaemia 52 Gaucher Disease 52 Neovascular AMD 52 Diabetic Patients 52 riociguat 52 Rheumatoid Arthritis Drug 52 Exacerbations 52 Complicated Skin 52 chronic Hepatitis B 52 lupus nephritis 52 Female Sexual Arousal 52 paroxysmal nocturnal hemoglobinuria 52 Pertuzumab 52 Epratuzumab 52 AKT inhibitor 52 Cardiac Marker 52 pneumocystis carinii pneumonia 52 Idiopathic Thrombocytopenic Purpura ITP 52 juvenile myelomonocytic leukemia 52 Ankylosing Spondylitis 52 Breast Cancer Recurrence 52 Hepatitis C HCV 52 gastrointestinal GI motility disorders 52 metastatic renal 52 chronic inflammatory bowel 52 exocrine pancreatic insufficiency 52 Crohn disease CD 52 Diffuse Large B 52 pancreatic neuroendocrine tumors 52 Stomach Cancer 52 Cryopyrin Associated Periodic Syndromes 51 Irritable Bowel Syndrome IBS 51 relapsed AML 51 Duchenne Becker 51 Rituxan rituximab 51 nucleoside analogue 51 functional mitral regurgitation 51 vWD 51 Inflammatory Markers 51 taxane chemotherapy 51 Wegener Granulomatosis 51 VNP#M 51 Systemic Juvenile Idiopathic 51 membranous nephropathy 51 lymphoma leukemia 51 active ankylosing spondylitis 51 Social Anxiety Disorder 51 Knee Osteoarthritis 51 Entry Inhibitor 51 anti angiogenic therapy 51 lorvotuzumab mertansine 51 hepatitis B HBV 51 secondary hyperparathyroidism 51 dyskeratosis congenita 51 Physician Insights 51 chronic immune thrombocytopenic 51 davunetide intranasal AL 51 Torisel 51 null responder 51 hematologic disorders 51 Respiratory Syncytial Virus RSV 51 homozygous familial hypercholesterolemia 51 limb ischemia 51 gastrointestinal stromal tumors 51 Von Willebrand disease 51 Copegus ribavirin 51 hypovitaminosis D 51 Stargardt Macular Dystrophy 51 Proxinium TM 51 POSIDUR TM 51 hereditary antithrombin deficiency 51 Mipomersen 51 TNF antagonist 51 relapsed acute myelogenous 51 atypical Hemolytic Uremic Syndrome 51 Chronic Myeloid Leukaemia 51 fibromyalgia syndrome 51 YONDELIS 51 fosbretabulin 51 nephropathic cystinosis cystinosis 51 albiglutide currently 51 Vicriviroc 51 Lennox Gastaut Syndrome 51 either acutely decompensated 51 Velcade bortezomib 51 gastric carcinoma 51 glufosfamide 51 1 Antitrypsin Deficiency 51 metastatic uveal melanoma 51 Angioedema 51 Insegia 51 Allovectin 7 51 Cethromycin 51 RNAi therapeutic targeting 51 Hepatotoxicity 51 polycythemia vera PV 51 Pleural Mesothelioma 51 erythematosus SLE 51 CMV retinitis 51 Immune Mediated 51 liver metastasis 51 CA4P 51 metastatic colorectal 51 Alzhemed TM 51 Clinical Efficacy 51 HBeAg negative 51 remission induction 51 3 registrational trial 51 brainstem glioma 51 AVN# Phase 51 metastatic renal cell 51 Immune Thrombocytopenic Purpura 51 Hepatitis B virus HBV 51 Hepatitis C Virus HCV 51 Respiratory Distress 51 thalassemia sickle cell 51 Ischemic Stroke 51 primary ciliary dyskinesia 51 Fanconi syndrome 51 Benign Prostatic Hyperplasia BPH 51 systemic lupus erythematosus 51 AAT Deficiency 51 gepirone ER 51 Transverse Myelitis 51 Hospital Acquired Pneumonia 51 metastatic GIST 51 hereditary medullary thyroid 51 FOLFOX6 chemotherapy regimen 51 cutaneous T 51 Wet AMD 51 BARACLUDE ® 51 Bipolar Depression 51 Drug Shows Promise 51 gastric adenocarcinoma 51 Stem Cell Transplant 51 chemotherapy cisplatin 51 refractory ovarian cancer 51 Chronic Prostatitis 51 hepatic tumors 51 Lung transplantation 51 rare autosomal recessive 51 Renal dysfunction 51 humanised antibody 51 PsA 51 Chronic Hepatitis C 51 cystic kidney 51 hepatitis C viral infection 51 antiretroviral naïve 51 Candesartan 51 Peripheral artery 51 inflammatory demyelinating 51 chronic opioid 51 acute lymphoblastic 51 Mouse Model 51 metastatic hormone refractory 51 Hemorrhagic 51 debilitating autoimmune 51 Relapsed Multiple Myeloma 51 Immune Thrombocytopenic Purpura ITP 51 cytomegalovirus retinitis 51 myeloproliferative disorders 51 diagnosed GBM 51 Duchenne muscular dystrophy DMD 51 Aliskiren 51 NICE Recommends 51 hepatic encephalopathy HE 51 surgically resectable 51 pediatric pontine glioma 51 spinal muscular atrophy SMA 51 Buerger Disease 51 stage IIIB IV 51 rindopepimut 51 deletion 5q 51 Disease Modifying 51 Combination Treatment 51 Multiple Myeloma MM 51 Elagolix 51 CP CPPS 51 Systemic Lupus Erythematosus 51 Eltrombopag 51 diabetic kidney 51 Kepivance 51 bevacizumab Avastin ® 51 Congestive Heart Failure 51 L Annamycin 51 GH deficiency 51 leukemia APL 51 vaso occlusive crisis 51 Nonalcoholic Steatohepatitis 51 metaglidasen 51 Phase IIA 51 Metastatic Prostate Cancer 51 Severe Asthma 51 polymyalgia rheumatica 51 Chronic HCV 51 Pirfenidone 51 Toxicities 51 Squamous 51 Chronic Myelogenous Leukemia CML 51 Generalized Anxiety Disorder GAD 51 Crohns disease 51 carcinoid syndrome 51 progressively degenerative 51 Protease Inhibitors 51 Cytomegalovirus 51 CIMZIA ™ 51 Sezary syndrome 51 TheraCIM 51 + Perifosine Evaluation 51 Non Hodgkins lymphoma 51 myeloproliferative disease 51 peritoneal carcinomatosis 51 diabetic macular edema 51 Akt inhibitor 51 gemcitabine carboplatin 51 mycosis fungoides 51 debilitating neurodegenerative 51 Vicinium TM 51 cirrhosis liver failure 51 GOUT 51 lumiliximab 51 idiopathic myelofibrosis 51 posterior uveitis 51 REVEAL Registry 51 COPD asthma 51 huC# DM4 51 Systemic lupus erythematosus SLE 51 BRIM3 51 JAK inhibitor 51 estramustine 51 hereditary deafness 51 de novo kidney transplant 51 Lou Gehrigs disease 51 Tiotropium 51 pediatric acute lymphoblastic 51 Chronic lymphocytic leukemia CLL 51 Placebo Controlled Study 51 Refractory Angina 51 HuMax EGFr 51 relapsed refractory multiple myeloma 51 IRESSA 51 malignant brain 51 neoadjuvant treatment 51 advanced metastatic renal 51 Kevetrin ™ 51 Host Disease GvHD 51 Oral Interventions 51 Bayer Nexavar 50 juvenile myoclonic epilepsy 50 decompensated liver disease 50 heavily pretreated 50 galiximab 50 Amyotrophic Lateral Sclerosis ALS 50 Fibrosis 50 Chronic Leukemia 50 Treatment Outcome 50 6R BH4 50 Hormone Refractory Prostate Cancer 50 e antigen HBeAg 50 Pneumococcal Vaccine 50 Lung Cancer Patients 50 Injury ALI 50 juvenile idiopathic arthritis 50 Liver Cancer 50 allogeneic hematopoietic cell 50 opioid induced constipation 50 vascular disrupting agent 50 Hepatitis B Virus 50 Fibromyalgia Syndrome 50 simplex virus 50 autoantibody positive 50 rALLy clinical trial 50 gastrointestinal malignancies 50 HIV HCV coinfected 50 lymphoid malignancies 50 TRC# 50 renal kidney 50 ALN TTR 50 autosomal recessive disorder 50 Graft Versus Host 50 gefitinib Iressa 50 Neurodegenerative 50 refractory NSCLC 50 Liver Failure 50 leukoencephalopathy 50 Cetuximab 50 graft dysfunction 50 Non Hodgkin 50 idiopathic pulmonary arterial hypertension 50 GI motility disorders 50 cilengitide 50 nucleotide analogue 50 Adenocarcinoma 50 urolithiasis 50 Tyrima 50 acute lymphoid leukemia 50 ER CHOP 50 Low Incidence 50 registrational Phase 50 epithelial tumors 50 cisplatin gemcitabine 50 multikinase inhibitor 50 MVA MUC1 IL2 50 postoperative delirium 50 Rheumatoid Arthritis Patients 50 myelofibrosis polycythemia vera 50 idiopathic PAH 50 Alzheimers Disease 50 Myoblast 50 entinostat 50 5 fluorouracil leucovorin 50 Occlusive Disease 50 EECP R 50 Voreloxin 50 PROCRIT ® 50 Eprodisate 50 Human Neural Stem 50 Left Ventricular 50 post thrombotic syndrome 50 Improved Survival 50 multicenter randomized placebo controlled 50 Sanfilippo Syndrome 50 cutaneous squamous cell carcinoma 50 Hepatic Encephalopathy 50 RhuDex R 50 SSc 50 recurrent ovarian cancer 50 Chronic Pelvic Pain 50 relapsed refractory AML 50 Treatable 50 vismodegib 50 optica 50 adult periodontitis 50 ® bortezomib 50 CCR5 antagonist 50 Duchene Muscular Dystrophy 50 malignant lymphoma 50 Gefitinib 50 Acute Radiation Syndrome 50 multicenter prospective 50 metastatic kidney 50 ANCA associated 50 Visceral Leishmaniasis 50 systemic lupus erythematosus psoriasis 50 visceral leishmaniasis VL 50 Vandetanib 50 Nimotuzumab 50 Deforolimus 50 Vaccine Candidate 50 Surgical resection 50 lumbar spinal stenosis LSS 50 terlipressin 50 acute promyelocytic leukemia 50 Adenomas 50 Initiated Phase 50 leukemia lymphomas 50 Gastrointestinal Stromal Tumors 50 Essential Tremor 50 Vaccine Shows Promise 50 plus DOXIL 50 Lateral Sclerosis 50 dyslipidaemia 50 Clostridium difficile Infection 50 Aneurysm Repair 50 nonalcoholic steatohepatitis 50 Nonalcoholic fatty liver 50 colorectal adenoma 50 alzheimer disease 50 Recurrent Chest Wall 50 metastatic renal cell carcinoma 50 pulmonary alveolar 50 squamous cell carcinoma SCC 50 Confirmatory 50 ulcerative colitis UC 50 Selective Internal 50 Hp2 2 50 malignant pleural mesothelioma 50 Peritoneal Dialysis 50 ATL# [001] 50 bullous 50 fibrosing 50 ophthalmological diseases 50 opioid induced bowel dysfunction 50 PLX MS 50 pancreatic adenocarcinoma 50 MPGN 50 Myotonic dystrophy 50 nasopharyngeal cancer 50 cinacalcet 50 Anti retroviral 50 tumor lysis syndrome 50 concurrent chemoradiation 50 Congenital Muscular Dystrophy 50 herpes zoster shingles 50 nucleotide analog 50 Spinal Cord Injuries 50 Treatment Reduces 50 Laquinimod 50 TTF Therapy 50 Inflammatory Bowel 50 hereditary spastic paraplegia 50 INCB# [001] 50 chemo radiotherapy 50 hypoxia activated prodrug 50 Klippel Trenaunay Syndrome 50 fluoropyrimidine 50 congenital muscular dystrophy 50 unresectable locally advanced 50 neuro degenerative disorder 50 neuroendocrine cancers 50 Optiquel ™ 50 Bipolar Mania 50 Genes Predict 50 Donepezil 50 Pamidronate 50 Potent Antiviral Activity 50 Chronic Hepatitis B 50 developing Bicifadine serotonin 50 SHPT 50 cutaneous lupus 50 Acute Coronary Syndromes